INTRODuCTION
Infantile hemangiomas (IH) are common benign tumors in infancy, affecting 5-10% of all infants, and up to 30% of premature newborns and chorionic villus sampling exposed infants (1, 2) . Although 85-90% of all IH eventually undergo spontaneous involution, they can still cause disfigurement and serious complications depending on their location (obstruction of airways and vision), size (cardiac insufficiency, hypothyroidism), and speed of regression, which can be associated with painful ulcerations and haemorrhage (3) . At birth, IH may not be apparent or may appear as flat circumscribed lesions with telangiectatic vessels on the surface. Within the first weeks of life, IH enter a phase of rapid growth with superficial and/or deep components, which lasts usually 3 to 6 months and sometimes up to 24 months. A period of stabilization for a few months follows, and spontaneous involution usually occurs in several years. Regression is complete for 60% of 4-year-old patients and 76% of 7-year-old patients (4) . The conventional approach in complicated cases is to use systemic corticosteroid therapy as first-line treatment and then interferon or vincristine as second -or third-line therapeutic agents. Unfortunately, each treatment option has limited therapeutic benefit with its own side-effect profile and risks (5) . In 2008, Leaute-Labrezeet and colleagues described their serendipitous observation of an antiproliferative effect of propranolol on IH. Propranolol has since become the first choice of therapy for complicated IH, even though randomized controlled studies have not been finished yet and a generally accepted concept of how propranolol actually works in IH does not exist (5, 6) . In this report, we want to present our initial experience with propranolol treatment of infantile hemangioma in Children's hospital, University clinical center Tuzla.
METHODS
We developed a treatment protocol to optimize safety: baseline echocardiography and cardiac ultrasound followed by72-hour hospitalization to monitor vital signs and blood glucose levels. Medication is given every 8 hours, with an initial dose of 0.5 mg per kilogram of body weight. If the vital signs and glucose levels remain normal, the dose is doubled to a maximum daily dose of 2 mg per kilogram. If infant tolerate propranolol, than could be discharged home. Follow-up consisted of monthly clinic visits to asset a therapy progress and eventual dosage adjustment. Propranolol should be gradually tapered over a period of 2 weeks. Hemangiomas undergoing propranolol therapy were photographed in series before and during their treatment cycle to document treatment response. Parents were asked to tell us about any side effects of treatment and overall satisfaction about propranolol treatment.
CASE REPORTS
Case 1: A 5-month-old female child presented by ophthalmologist with a hemangioma at lower eyelid and hemangioma on perianal region. Parents were complaining about hemorrhage from perianal hemangioma after defecation ( Figure 1 ). On admission, a thorough physical examination was performed followed by electrocardiogram, cardiac ultrasound, blood sugar level and vital signs. After ruling out asthma and allergy, propranolol treatment was gradually increased by protocol to maximum dosage of 2 mg per kilogram per day in three doses. Within 72 hours of Case 2: A 11 month old female infant presented with a large hemangioma on neck, measured 6x5 cm, confirmed by MRI ( Figure 3 ). Bulge on the neck started to be noticeable at 3th month of life. The patient was investigated as in case 1, and the same dose regimen for propranolol was followed (2 mg/kg/ day in three divided doses). Within 10 days of giving this dose, the swelling decrease to half of original size. After 6 month of treatment neck hemangioma showed notable regression to less than 1 cm in diameter ( Figure 4 ).
Case 3: A 3-month-old male infant presented with a hemangioma of nose with progressive growth from second month of life with left periorbital expansion. Propranolol therapy was introduced according to standard protocol to therapeutic dosage (2mg/kg/day in three doses). After 6 month of treatment there was near total regression of hemangioma ( Figure 5) .
In all three cases there weren't any side effects of propranolol therapy. Thereafter, the dose was gradually tapered over 2 weeks and stopped. Regular monthly post-treatment follow up of both the patients did not show any rebound of hemangioma. Parents of all patients were overall satisfied with treatment.
DISCuSSION
Although the majority of IH have little impact on childhood health, various problematic head and neck hemangiomas will develop rapidly and interfere with normal function and appearance (5). The proposed mechanism for the action of propranolol is that it induces vasoconstriction and capillary endothelial cell apoptosis (7). Potential explanations for the therapeutic effect of propranolol -a nonselective beta-blocker -on infantile capillary hemangiomas include vasoconstriction, which is immediately visible as a change in color, associated with a palpable softening of the hemangioma; decreased expression of VEGF and bFGF genes through the down-regulation of the RAF-mitogen-activated protein kinase pathway (which explains the progressive improvement of the hemangioma); and the triggering of apoptosis of capillary endothelial cells (8) . Nevertheless, several case studies have further provided evidence of the dramatic effect of propranolol on massive, proliferating, life threatening, and involuting lesions (5, 8, 10) . Systemic corticoids, long considered as the therapy of choice for hemangioma of infancy, have hard to control insidious adverse effects, besides variable response (11) . The use of alpha-interferon is described in the literature with good results, although with the inconvenience of being a prolonged intravenous treatment that has significant adverse effects (12) . Due to the limited literature and research available on the impact of propranolol on hemangiomas and other vascular tumors, a precise protocol for its clinical use does not yet exist. Treatment protocol that is adopted in our institution is based on guidelines regarding the appropriate patients, followup and dosing adjustments to reduce unwanted cardiopulmonary or systemic effects of propranolol. Experience from other authors (9, 11, 12) , including our, has shown good outcomes regarding lesion involution, with few adverse effects connected with the propranolol.
CONCLuSION
A l l ment ioned above, st ated that propranolol is novel and safe medication for treatment of infantile hemangioma. The cases described presented HI regression similar to that observed in other studies. It has a tolerable side-effect profile, and there have been no serious side effects reported in appropriately screened patients. 
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